NFKB1 and diffuse large B-cell lymphoma: This is seen in MYD88 DLBCLs where MYD88 mutations promote NF-κB signaling, encouraging cell proliferation and survival, while also promoting the production of interferon-beta (IFNβ) which is cytotoxic to DLBCL cells (Yang et al., 2012).